Search results
Found 16 matches for
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.
Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF
Arthritis Kennedy Main
11 March 2021
New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).
A new study maps the expression of innate immune receptors during the course of arthritis
Arthritis Kennedy Main
8 March 2021
The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.
A more tailored approach to treating psoriatic arthritis
Arthritis Botnar Funding Main
8 January 2021
Dr Laura Coates has been awarded £1.8M from the National Institute for Health Research (NIHR) to explore the potential for precision medicine in the choice of biologics to reduce inflammation and pain in psoriatic arthritis.
New breakthrough in the treatment of rheumatoid arthritis
Arthritis Kennedy Main
25 November 2020
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.
Key discovery in Psoriatic Arthritis points way for developing targeted treatments
Arthritis Main
21 September 2020
A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers from the University of Oxford and the Wellcome Sanger Institute identified high levels of a specific receptor in immune cells from psoriatic arthritis patients, giving the strongest evidence yet of a single cause for the disease.
Workload linked with an increased risk of knee osteoarthritis
Arthritis Main
9 September 2020
Men and women working in heavy manual occupations are twice as likely to suffer from knee osteoarthritis (OA), the most common joint disorder, compared to those in sedentary occupations according to a new study published in the prestigious journal Seminars in Arthritis and Rheumatism.
Numerous jobs linked to increased risk of knee osteoarthritis
Arthritis Main
23 July 2020
Stay-at-home parents, cleaners, and blue-collar workers found to be more likely to develop osteoarthritis
Joint cell discovery offers new hope for people with rheumatoid arthritis
Arthritis Kennedy Main
29 June 2020
The key to swift treatments to cure the pain of rheumatoid arthritis has been found in the joints of people with the condition who are in long- term remission.
Researchers identify markers in joint fluid that could be the key to cartilage repair
Arthritis Kennedy Knee Main
9 March 2020
Molecular changes in the joint fluid during surgical joint distraction reveal markers that may drive cartilage repair in osteoarthritis.
New therapeutic target identified in spondyloarthritis
Arthritis Kennedy Main
20 January 2020
A new study published in Nature Communications identifies a key driver of joint and intestinal inflammation that could lead to future treatment of the chronic inflammatory disease.
Key link discovered between tissue cell type and different forms of arthritis
Arthritis Kennedy Main Publication Translational medicine
29 May 2019
Pioneering research by scientists at the Universities of Oxford and Birmingham published today in Nature brings us a step closer to developing targeted therapies for inflammatory diseases.
Study reveals new drug target for rheumatoid arthritis
Arthritis Kennedy Main
28 May 2019
New research at the Kennedy Institute reveals potential of a novel class of drugs for the treatment of rheumatoid arthritis.
UKRI Future Leaders Fellowship to Dr Fiona Watt
Arthritis Awards Main
7 May 2019
Dr Fiona Watt has been awarded a prestigious UK Research and Innovation (UKRI) Future Leaders Fellowship to further her research for better treatments for people living with, or at risk of the commonest form of arthritis, osteoarthritis.
New approach could bring closer a cure for a painful form of arthritis
Arthritis Awards Main
1 April 2019
Dr Liye Chen has been awarded a Versus Arthritis five-year career development fellowship to identify and validate new T cell therapeutic targets in ankylosing spondylitis (AS).
Showcasing a new approach to arthritis research
Arthritis Kennedy Main
27 March 2019
A recent workshop at Pembroke College, Oxford, provided a showcase for research within the Arthritis Therapy Acceleration Programme (A-TAP) aimed at speeding up the delivery of new drugs for immune-mediated inflammatory disease (IMIDs).
New drug class could offer a targeted safer treatment alternative for patients with rheumatoid arthritis
Arthritis Kennedy Main Publication Research
15 February 2019
A new treatment targeting tenascin-C could reduce the progression and severity of rheumatoid arthritis (RA) at the very early stages of disease.
Meet Chris
-
Christopher Buckley
Senior Clinical Research Fellow, Director of Clinical Research
Funded by
Find out more about
Similar stories
Professor Katja Simon elected to the Academy of Medical Sciences
12 May 2021
Professor of Immunology Katja Simon has been elected as a Fellow of the Academy of Medical Sciences.
3,400 different medicines used globally to treat COVID-19
11 May 2021
Main Statistics and epidemiology
Insufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study
Clinical trial finds Azithromycin has no benefit against COVID-19
6 May 2021
A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.
Study reveals the three most important aspects of care for hip fractures
5 May 2021
Hip Main OCTRU Research Trauma
Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.
Major ERC funding awarded to Professor Michael Dustin
4 May 2021
Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.
The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19
30 April 2021
Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?